Companies · Wholesale · 🇺🇸

Cencora

COR · NYSE/NASDAQ · Wholesale · $309 a share (close of 02 Oct 2026)

Available company data, source links and archived checks for Cencora. Read each source and date: a past check is not a fresh review, and some earlier figures have incomplete source details.

Revenue rose 5.1%; Net profit was $763.52 million.

Quarter ended 2026-06-30 · consolidated · Company filing

Recorded quarterly figures
QuarterRevenue / incomeYoY ProfitYoYNet marginSource
Jun 2026Revenue: $84.8 bn+5.1%Net profit: $764 mn+11.1%0.9%Company filing source
Mar 2026Revenue: $78.4 bn+3.8%Net profit: $1.6 bn+128.6%2.1%Company filing source
Dec 2025Revenue: $85.9 bn+5.5%Net profit: $560 mn+14.5%0.7%Company filing source
Sep 2025Revenue: $83.7 bn+5.9%Net profit: $-340 mn-10144.5%-0.4%Company filing source
Jun 2025Revenue: $80.7 bn+8.7%Net profit: $687 mn+42.2%0.9%Company filing source
Mar 2025Revenue: $75.5 bn+10.3%Net profit: $718 mn+70.6%1.0%Company filing source

YoY means change from the same quarter a year earlier. — means no comparable figure is available. Older entries with incomplete source details have not been revalidated under the current checks.

Recently checked facts

A number of our contracts with customers, including group purchasing organizations, are typically subject to expiration each year. We may lose a key customer if an existing contract with such customer expires without being extended, renewed, or replaced. Over the next twelve months, there are no key contracts scheduled to expire. Additionally, from time to time, key contracts may be terminated in accordance with their terms or extended, renewed, or replaced prior to their expiration dates. If those contracts are extended, renewed, or replaced at less favorable terms, they may also negatively impact our revenue, results of operations, and cash flows.

30

Table of Contents

Gross Profit

✓ verified by reading the document archived check · 2026-09-28 SEC filing →

A recoverability assessment of PharmaLex's long-lived asset group as of July 1, 2025 determined it recoverable.

✓ verified by reading the document archived check · 2026-09-28 SEC filing →

A recoverability assessment of PharmaLex's long-lived asset group as of July 1, 2025 determined it was recoverable.

✓ verified by reading the document archived check · 2026-09-28 SEC filing →

A reserve is recorded only when a liability is probable and reasonably estimable.

✓ verified by reading the document archived check · 2026-09-28 SEC filing →

Acquisitions are recorded at estimated fair value with the residual purchase price as goodwill, and results are included from the acquisition date.

✓ verified by reading the document archived check · 2026-09-28 SEC filing →
The ownership tape — last 90 days, from disclosures
▼ Greenberg Lon R (Director) sold shares worth $411k · 16 Sep · SEC Form 4
▼ Krikorian Lazarus (SVP & Chief Accounting Officer) sold shares worth $321k · 01 Sep · SEC Form 4
▼ Campbell Elizabeth S (Executive Vice President) sold shares worth $3.7 million · 24 Aug · SEC Form 4
Who holds it — from the filings
BlackRock, Inc.VANGUARD CAPITAL MANAGEMENT LLCVANGUARD PORTFOLIO MANAGEMENT LLCSTATE STREET CORPGEODE CAPITAL MANAGEMENT, LLCregister as filed 2026-08-31
Filing timeline — what the company told the exchange

Follow this company without reading every document yourself.

Keep its available filings, dated fact checks and disclosure alerts together. Your saved country sets your market and its research schedule.

Start free — first week on us →
India ₹149/month · Rest of world US$4.99/month after the free trial · research, not investment advice · cancel any time
Or just the free morning: three facts checked against filings, every trading day, in your inbox.

Company data and archived claim checks are shown with available sources. Check the source and date before relying on a figure. This is not investment advice or a recommendation. Investment in securities markets is subject to market risks. Research on this site is produced with substantial use of AI. Terms, disclosures and grievances